Greg Medlock from Vedanta Biosciences shares how he is using automation to power discovery of microbiome therapeutics.

Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s pipeline includes clinical-stage product candidates being evaluated for the prevention of recurrent C. difficile infection and inflammatory bowel diseases and a preclinical candidate for the prevention of Gram-negative infections. Each product candidate is a defined consortia of bacteria that have been lyophilized and filled in enteric-coated capsules.